Legend Biotech, the global biotech company developing, manufacturing and commercialising novel therapies to treat life-threatening diseases, has announced the appointment of Mythili Koneru, M.D., Ph.D. as Chief Medical Officer (CMO).
In the role, Dr Koneru will be responsible for overseeing the Company’s clinical development and medical affairs programmes.
Ying Huang, CEO of Legend Biotech, said:
“On behalf of the Company, I am pleased to welcome Dr Koneru to the Legend team.
“Dr Koneru brings a wealth of knowledge in the field of immunotherapy and cell therapy, with extensive experience in designing early-stage clinical trials for hematologic malignancies and solid tumours.
“We look forward to her leadership and contributions to our organisation, as we continue to advance our pipeline of cell-based therapies and bring innovative therapies to clinic.”
Dr Koneru joins Legend Biotech from Marker Therapeutics, where she served as its CMO, leading the development of the company’s cell therapies and peptide vaccines in its immuno-oncology portfolio.
Before that, Dr Koneru served as Associate Vice President of Immuno-Oncology at Eli Lilly and Company, where she focused on the clinical development of immuno-oncology assets in the company’s early phase oncology portfolio.
Dr. Koneru was also an Oncology Fellow at Memorial Sloan-Kettering Cancer Center, where she developed adoptive T-cell therapies in both leukaemia and solid tumour malignancies in early phase clinical trials.
Dr. Koneru obtained her B.A. in Cellular and Molecular Biology from the University of Chicago, a Ph.D. in Biomedical Research: Tumour Immunology from New York University, and an M.D. from Robert Wood Johnson Medical School.
Headquartered in Somerset, New Jersey, Legend Biotech is developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy.
